Browse the corpus

Aflibercept is an anti-vascular endothelial growth factor (VEGF) medication approved for the treatment and management of neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema, macular edema secondary to retinal vein occlusion, diabetic retinopathy, and retinopathy of prematurity. Aflibercept is a humanized recombinant fusion protein that functions as a soluble decoy for VEGF receptors, also known as "VEGF trap," which is designed to inhibit the predominant signaling pathways mediating pathological angiogenesis and vascular permeability. The drug demonstrates high-affinity binding to VEGF-A, VEGF-B, and placental growth factor, with sufficient retinal penetration to achieve effective and sustained VEGF inhibition. Aflibercept and other anti-VEGF agents have become the gold standard in the management of nAMD. Ongoing clinical research continues to explore the therapeutic potential of aflibercept in a broader range of exudative retinal diseases, with approved indications steadily expanding. This activity reviews the mechanism of action, dosing strategies, pharmacodynamics, pharmacokinetics, safety profile, monitoring requirements, and clinically relevant interactions of aflibercept, which are essential factors for members of the interprofessional healthcare team in treating patients with exudative retinal diseases. The activity also discusses the current evidence base supporting the efficacy of aflibercept, along with potential areas for future research and advancement. In addition, this activity highlights the importance of interprofessional collaboration among healthcare providers to optimize patient outcomes. Objectives: Identify the FDA-approved indications and off-label uses of aflibercept in managing retinal vascular diseases. Implement evidence-based intravitreal injection protocols to minimize the risk of complications such as endophthalmitis or retinal detachment. Apply risk stratification strategies for patients with comorbid conditions (eg, diabetes, cardiovascular disease, and renal impairment) to optimize safety. Collaborate with interprofessional healthcare providers to coordinate long-term monitoring and management of disease recurrence, adverse events, and treatment-related complications. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose Aflibercept is intended for IVT administration to achieve local effects within the eye, allowing penetration of all retinal layers while minimizing systemic exposure. Studies exposing cultured corneal endothelial cells to varying concentrations of aflibercept have shown no cytotoxic effects.[51] However, there is potential for drug overdose with IVT aflibercept therapy due to slight misalignment of the plunger in prefilled syringes. These small mismeasurements can result in the administration of up to twice the intended volume of medication. Aflibercept overdose accounts for multiple transient IOP elevations since its introduction. IOP should be monitored using a Goldmann applanation tonometer.[52] Management of Overdose No specific antidote exists for aflibercept overdose. Adhering strictly to the recommended instructions for use can help minimize dosing errors and reduce the risk of toxicity from IVT aflibercept.[53]

Aflibercept is a humanized recombinant fusion protein indicated for intraocular use. IVT injection is indicated for the treatment of nAMD, macular edema associated with RVO, DME, diabetic retinopathy, and ROP. Accurate diagnosis and timely management of these ocular diseases can significantly improve a patient's quality of life. Managing the treatment of ocular disease characterized by abnormal angiogenesis, such as nAMD and diabetic retinopathy, requires an interprofessional approach involving healthcare providers, including physicians, specialists, advanced practice providers, nurses, and pharmacists, to ensure effective and coordinated treatment.[2][3] To ensure patient safety, the specific roles of each healthcare team member should be clearly defined, and all medical personnel should be adequately trained for their responsibilities. The team members include healthcare practitioners, specialists, technicians, surgical assistants, and optometrists. Clinical ophthalmic technicians are responsible for updating patient histories, measuring visual acuity, and assessing IOP before the retinal specialist evaluates the patient. Clinical technicians also perform imaging studies such as optical coherence tomography (OCT) and fundus photography. OCT provides cross-sectional images of the retina, allowing assessment of individual layers, evaluation of disease progression, and measurement of treatment response. When therapy is indicated, ophthalmic technicians counsel patients regarding the potential risks and benefits before obtaining informed consent for the procedure. During the procedure, nurses review the timeout sheet to confirm the correct eye, procedure, and medication to be administered to the patient. Surgical assistants prepare the procedure tray, gown and drape the patient, clean and disinfect the injection site, and assist the clinician during administration. Specialists follow standardized protocol guidelines to ensure the safe administration of IVT aflibercept. Technicians may administer post-injection antibiotics, remove the patient's drape, and wash the eye with a basic saline solution. They also provide post-injection care instructions and schedule follow-up appointments. Optometrists play an essential role in closely monitoring the patient's response to aflibercept therapy during subsequent visits.[54]

Technicians may administer post-injection antibiotics, remove the patient's drape, and wash the eye with a basic saline solution. They also provide post-injection care instructions and schedule follow-up appointments. Optometrists play an essential role in closely monitoring the patient's response to aflibercept therapy during subsequent visits.[54] Patients should be educated and monitored for signs of elevated IOP and also advised to contact or return to the clinic if they begin to experience severe eye pain after receiving an injection. All healthcare team members must continue to monitor the patient during each interaction and document their observations in the medical record. If they notice any concerns, including therapeutic failure or adverse events, they must immediately communicate these to the appropriate team members to facilitate additional evaluation, which can potentially lead to corrective action.[46] Patient self-monitoring is crucial for detecting signs of infection and decreased visual acuity. An interprofessional, team-based approach involving clinicians, specialists, optometrists, ophthalmic technicians, and patients leads to desired therapeutic outcomes, minimizes the risk of disease progression, and improves the overall quality of life of patients.